Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

msh id	COM:ROIVANT
symbol	ROIV
name	Roivant Sciences Ltd.
homepage url	https://roivant.com
country	GB
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	908
crunchbase url	-
linkedin url	-
founders	-

market cap	8.31B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	13.29K
monthly webtraffic growth	-0.61
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.1
growth cost of revenue	0.46
growth depreciation and amortization	0.9
growth ebitda	0.26
growth ebitda ratio	0.33
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.23
growth gross profit	0.04
growth gross profit ratio	-0.06

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

11.82

21/11 22:03

Market Cap

8.31B

Beta: -

Volume Today

7.11M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.14B
cost of revenue	1.14B
depreciation and amortization	-30.01M
ebitda	-1.11B
ebitda ratio	-18.07
eps	-1.73
eps diluted	-1.73
operating expenses	1.13B
operating income	-1.08B
operating income ratio	-17.58

accounts receivables	-
capital expenditure	-12.69M
cash at beginning of period	2.07B
cash at end of period	1.69B
inventory	2.76M
working capital ttm	1.29B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-